サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1725796

膣抗真菌薬の世界市場：産業分析、規模、シェア、成長、動向、予測、2025年～2032年

Vaginal Antifungals Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 250 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.06円
膣抗真菌薬の世界市場：産業分析、規模、シェア、成長、動向、予測、2025年～2032年
出版日: 2025年05月15日
発行: Persistence Market Research
ページ情報: 英文 250 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Researchはこのほど、世界の膣抗真菌薬市場に関する包括的なレポートを発表しました。当レポートでは、市場促進要因・動向・機会・課題などの重要な市場力学を徹底的に評価し、市場構造に関する詳細な洞察を提供しています。この調査レポートは、2025年～2032年の世界の膣抗真菌薬市場の予測成長軌道を概説する独占データと統計を掲載しています。

主な洞察

  • 膣抗真菌薬の市場規模（2025年）：11億3,360万米ドル
  • 市場予測金額（2032年）：13億7,530万米ドル
  • 世界市場成長率（CAGR 2025～2032年）：2.8%

膣抗真菌薬市場：調査範囲

膣抗真菌薬は、一般的にカンジダ種によって引き起こされる外陰膣カンジダ症などの真菌感染症の治療に使用される必須医薬品です。これらの治療は、クリーム、座薬、錠剤、軟膏など様々な形態で提供されており、処方箋に基づく使用と一般用医薬品（OTC）の使用の両方に対応しています。市場は婦人科クリニック、小売薬局、オンライン・プラットフォーム、病院にサービスを提供しています。女性の健康に対する意識の拡大、膣感染症の増加、抗真菌治療薬へのアクセスの向上が市場開拓に大きく貢献しています。

市場促進要因：

世界の膣抗真菌薬市場は、多くの重要な要因によって牽引されています。生活習慣に関連した感染症の急増、抗生物質の使用量の増加、糖尿病患者の増加などが、真菌感染症の再発率の上昇に寄与しています。さらに、迅速かつ効果的で、目立たない治療オプションに対する消費者の嗜好が、OTC抗真菌製品に対する需要の急増につながっています。徐放性製剤や併用療法などの製品革新により、利便性と治療アドヒアランスが向上しています。特に都市部や半都市部では、月経や膣の健康に対する意識を高めるキャンペーンが、製品の認知度と普及率をさらに高めています。

市場抑制要因：

有望な成長が見込まれてはいますが、膣抗真菌薬市場には、低所得地域における認知度の低さ、膣の健康について語ることに対する社会的烙印、抗真菌薬耐性への懸念の高まりなどの課題があります。誤診や自己治療が不適切な治療につながり、全体的な有効性と消費者の信頼を低下させる可能性があります。規制上の制約、特に新しい製剤や配合剤については、市場参入の妨げとなり、承認が遅れる可能性があります。地域によっては、文化的障壁や教育不足が真菌感染症の過小診断や過小治療の一因となっています。

市場機会：

膣抗真菌薬市場の好機は、個別化された自然な治療オプションに対する需要の高まりに起因します。植物性製剤やプロバイオティクスを配合した製剤の動向が高まっており、技術革新の余地があります。遠隔医療サービスの拡大により、慎重な診察が可能となり、治療へのアクセスが拡大します。製薬会社と女性向けウェルネス・プラットフォームとの提携により、より広範な市場への浸透が可能になります。特にアジア太平洋とラテンアメリカでeコマース基盤が拡大し、OTC抗真菌薬メーカーに新たな収益源をもたらしています。診断ツールや自己検査キットの充実も、抗真菌療法のクロスセリング機会を生み出しています。

本レポートで扱う主な質問

  • 世界の膣抗真菌薬市場の成長を促進している主な要因は何か？
  • 異なる消費者層で最も好まれる剤形と製剤は何か？
  • 消費者行動の変化やeコマースの動向は膣抗真菌薬市場にどのような影響を与えているか？
  • 市場の主要企業はどこか、また成長を維持するためにどのような戦略を採用しているか？
  • 膣抗真菌薬市場の新たなビジネスチャンスと長期的展望は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲/分類
  • 市場の定義/対象範囲/制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主要な動向
  • 主要なイノベーション/開発動向

第4章 重要成功要因

  • 主要メーカーによるプロモーション戦略
  • 主な規制
  • 償還シナリオ
  • パイプライン分析
  • バリューチェーン分析
  • PESTEL分析
  • ポーターの分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因：関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 薬剤別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 2021年の市場シナリオ

第7章 世界の膣抗真菌薬市場の需要（金額または規模）分析、2019年～2024年

  • 過去の市場金額分析、2019年～2024年
  • 現在および将来の市場金額予測、2025～2032年
    • 前年比成長動向分析
    • 絶対的収益機会分析

第8章 世界の膣抗真菌薬市場分析：薬剤別（2019年～2024年）

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：薬剤別（2019年～2024年）
  • 現在・将来の市場規模分析・予測：薬剤別（2025年～2032年）
    • フルコナゾール
    • ナイスタチン
    • フルシトシン
    • クロトリマゾール
    • ケトコナゾール
    • テルビナフィン
    • その他
  • 医薬品別の市場の魅力分析

第9章 世界の膣抗真菌薬市場分析：投与経路別（2019年～2024年）

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：投与経路別（2019年～2024年）
  • 現在・将来の市場規模分析・予測：投与経路別（2025年～2032年）
    • 経口
    • 局所
  • 投与経路別の市場の魅力分析

第10章 世界の膣抗真菌薬市場分析：流通チャネル別（2019年～2024年）

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：流通チャネル別（2019年～2024年）
  • 現在・将来の市場規模分析・予測：流通チャネル別（2025年～2032年）
    • 院内薬局
    • 小売薬局
    • オンライン薬局
  • 流通チャネル別の市場の魅力分析

第11章 世界の膣抗真菌薬市場分析：地域別（2019年～2024年）

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：地域別（2019年～2024年）
  • 現在・将来の市場規模分析・予測：地域別（2025年～2032年）
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ
  • 地域別の市場の魅力分析

第12章 北米の膣抗真菌薬市場分析、2019年～2024年

第13章 ラテンアメリカの膣抗真菌薬市場分析、2019年～2024年

第14章 欧州の膣抗真菌薬市場分析、2019年～2024年

第15章 東アジアの膣抗真菌薬市場分析、2019年～2024年

第16章 南アジアの膣抗真菌薬市場分析、2019年～2024年

第17章 オセアニア膣抗真菌薬市場分析、2019年～2024年

第18章 中東・アフリカ（MEA）の膣抗真菌薬市場分析、2019年～2024年

第19章 市場構造分析

  • 企業階層別の市場分析
  • 市場集中
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第20章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細
    • Pfizer Inc.
    • Bausch Health Companies Inc
    • ANI Pharmaceuticals, Inc.
    • Hikma Pharmaceuticals Plc
    • Lupin Limited
    • Mycovia Pharmaceuticals, Inc.
    • Glenmark Pharmaceuticals Limited
    • Unique Pharmaceuticals
    • PEPTONIC medical AB
    • Aurobindo Pharma Limited
    • Dr. Reddy's Laboratories
    • SCYNEXIS, Inc.
    • Basilea Pharmaceutica Ltd.
    • Astellas Pharma Inc.
    • Grupo Ferrer Internacional, SA
    • Pacgen Life Science Corporation
    • NovaDigm Therapeutics, Inc.
    • Cidara Therapeutics, Inc.
    • Amplyx Pharmaceuticals Inc.

第21章 前提条件と使用される頭字語

第22章 調査手法

目次
Product Code: PMRREP33292

Persistence Market Research has recently released a comprehensive report on the worldwide market for vaginal antifungals. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global vaginal antifungals market from 2025 to 2032.

Key Insights:

  • Vaginal Antifungals Market Size (2025E): USD 1,133.60 Million
  • Projected Market Value (2032F): USD 1,375.30 Million
  • Global Market Growth Rate (CAGR 2025 to 2032): 2.8%

Vaginal Antifungals Market - Report Scope:

Vaginal antifungals are essential medications used to treat fungal infections such as vulvovaginal candidiasis, commonly caused by Candida species. These treatments are available in various forms, including creams, suppositories, tablets, and ointments, catering to both prescription-based and over-the-counter (OTC) usage. The market serves gynecology clinics, retail pharmacies, online platforms, and hospitals. Growing awareness about women's intimate health, rising incidences of vaginal infections, and increased accessibility to antifungal treatments contribute significantly to market development.

Market Growth Drivers:

The global vaginal antifungals market is driven by a number of key factors. A surge in lifestyle-related infections, increased antibiotic use, and a rise in diabetic populations have all contributed to higher rates of recurrent fungal infections. Moreover, consumer preference for quick, effective, and discreet treatment options has led to a spike in demand for OTC antifungal products. Product innovation, such as extended-release formulations and combination therapies, enhances convenience and treatment adherence. Campaigns promoting menstrual and vaginal health awareness further boost product visibility and adoption, especially in urban and semi-urban regions.

Market Restraints:

Despite encouraging growth prospects, the vaginal antifungals market encounters challenges including limited awareness in low-income regions, social stigma around discussing vaginal health, and the growing concern of antifungal resistance. Misdiagnosis and self-medication can lead to improper treatment, reducing overall efficacy and consumer trust. Regulatory constraints, especially for newer formulations and combination products, can hinder market entry and delay approvals. In some regions, cultural barriers and lack of education contribute to underdiagnosis and undertreatment of fungal infections.

Market Opportunities:

Opportunities in the vaginal antifungals market stem from increasing demand for personalized and natural treatment options. The rising trend of plant-based and probiotic-infused formulations provides scope for innovation. Expansion of telehealth services allows discreet consultations, expanding treatment access. Partnerships between pharmaceutical companies and women's wellness platforms enable broader market penetration. Growing e-commerce infrastructure, particularly in Asia Pacific and Latin America, is opening up new revenue streams for manufacturers of OTC antifungal solutions. Enhanced diagnostic tools and self-test kits also create cross-selling opportunities for antifungal therapies.

Key Questions Answered in the Report:

  • What are the primary drivers accelerating the growth of the vaginal antifungals market worldwide?
  • Which dosage forms and formulations are most preferred across different consumer segments?
  • How are changing consumer behaviors and e-commerce trends impacting the vaginal antifungals landscape?
  • Who are the leading players in the market, and what strategies are being adopted to sustain growth?
  • What are the emerging opportunities and long-term outlook for the vaginal antifungals market?

Competitive Intelligence and Business Strategy:

Prominent players in the vaginal antifungals market, including Lupin Limited, Pfizer Inc., and Bausch Health Companies Inc, are focusing on developing user-centric products that combine efficacy with comfort. Companies are increasingly investing in R&D to introduce extended-release suppositories, multi-symptom relief creams, and probiotic-integrated products. Strategic collaborations with gynecological associations and wellness influencers help increase awareness and product credibility. In addition, expanding retail presence and digital marketing strategies are enabling brands to reach younger, digitally-savvy consumers seeking accessible and private treatment options.

Key Companies Profiled:

  • Pfizer Inc.
  • Bausch Health Companies Inc
  • ANI Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals Plc
  • Lupin Limited
  • Mycovia Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Limited
  • Unique Pharmaceuticals
  • PEPTONIC medical AB
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories
  • SCYNEXIS, Inc.
  • Basilea Pharmaceutica Ltd.
  • Astellas Pharma Inc.
  • Grupo Ferrer Internacional, S.A.
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc.
  • Cidara Therapeutics, Inc.
  • Amplyx Pharmaceuticals Inc.

Vaginal Antifungals Industry Research Segments

By Drug:

  • Fluconazole
  • Nystatin
  • Flucytosine
  • Clotrimazole
  • Ketoconazole
  • Terbinafine
  • Others

By Route of Administration:

  • Oral
  • Topical

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Key Innovation / Development Trends

4. Key Success Factors

  • 4.1. Promotional Strategies, By Key Manufacturers
  • 4.2. Key Regulations
  • 4.3. Reimbursement Scenario
  • 4.4. Pipeline Analysis
  • 4.5. Value Chain Analysis
  • 4.6. PESTEL Analysis
  • 4.7. Porter's Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure Outlook
    • 5.1.3. Global Antifungal Drugs Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Impact of the COVID-19 Pandemic
    • 5.2.2. Increasing Product Launch Activities
    • 5.2.3. Prevalence of Vaginal Fungal Infections in HRT Patients
    • 5.2.4. High Rates of Vulvovaginal Candidiasis
    • 5.2.5. Impact on Quality-of-Life
    • 5.2.6. Increasing Number of People with Predisposing Conditions Such as Diabetes Treated with SGLT2 Inhibitors
    • 5.2.7. Growing Problems of Azole Resistance
    • 5.2.8. Toxicity of Antifungal Drugs
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Drug
    • 6.1.2. By Route of Administration
    • 6.1.3. By Distribution Channel
    • 6.1.4. By Country
  • 6.2. 2021 Market Scenario

7. Global Vaginal Antifungals Market Demand (in Value or Size in US$ Mn) Analysis 2019-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2024
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2025-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Vaginal Antifungals Market Analysis 2019-2032, By Drug

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Drug, 2019-2024
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug, 2025-2032
    • 8.3.1. Fluconazole
    • 8.3.2. Nystatin
    • 8.3.3. Flucytosine
    • 8.3.4. Clotrimazole
    • 8.3.5. Ketoconazole
    • 8.3.6. Terbinafine
    • 8.3.7. Others
  • 8.4. Market Attractiveness Analysis By Drug

9. Global Vaginal Antifungals Market Analysis 2019-2032, By Route of Administration

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2019-2024
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2025-2032
    • 9.3.1. Oral
    • 9.3.2. Topical
  • 9.4. Market Attractiveness Analysis By Route of Administration

10. Global Vaginal Antifungals Market Analysis 2019-2032, By Distribution Channel

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2024
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2025-2032
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Vaginal Antifungals Market Analysis 2019-2032, By Region

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2024
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2025-2032
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. East Asia
    • 11.3.5. South Asia
    • 11.3.6. Oceania
    • 11.3.7. Middle East and Africa
  • 11.4. Market Attractiveness Analysis By Region

12. North America Vaginal Antifungals Market Analysis 2019-2032

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 12.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Drug
    • 12.3.3. By Route of Administration
    • 12.3.4. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Drug
    • 12.4.3. By Route of Administration
    • 12.4.4. By Distribution Channel
  • 12.5. Market Trends
  • 12.6. Key Market Participants - Intensity Mapping
  • 12.7. Drivers and Restraints - Impact Analysis
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. U.S. Vaginal Antifungals Market Analysis
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast By Market Taxonomy
        • 12.8.1.2.1. By Drug
        • 12.8.1.2.2. By Route of Administration
        • 12.8.1.2.3. By Distribution Channel
    • 12.8.2. Canada Vaginal Antifungals Market Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast By Market Taxonomy
        • 12.8.2.2.1. By Drug
        • 12.8.2.2.2. By Route of Administration
        • 12.8.2.2.3. By Distribution Channel

13. Latin America Vaginal Antifungals Market Analysis 2019-2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 13.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
    • 13.3.1. By Country
      • 13.3.1.1. Mexico
      • 13.3.1.2. Brazil
      • 13.3.1.3. Argentina
      • 13.3.1.4. Rest of Latin America
        • 13.3.1.4.1. By Country
        • 13.3.1.4.2. By Drug
        • 13.3.1.4.3. By Route of Administration
        • 13.3.1.4.4. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Drug
    • 13.4.3. By Route of Administration
    • 13.4.4. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Mexico Vaginal Antifungals Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast By Market Taxonomy
        • 13.8.1.2.1. By Drug
        • 13.8.1.2.2. By Route of Administration
        • 13.8.1.2.3. By Distribution Channel
    • 13.8.2. Brazil Vaginal Antifungals Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast By Market Taxonomy
        • 13.8.2.2.1. By Country
        • 13.8.2.2.2. By Drug
        • 13.8.2.2.3. By Route of Administration
        • 13.8.2.2.4. By Distribution Channel
    • 13.8.3. Argentina Vaginal Antifungals Market Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast By Market Taxonomy
        • 13.8.3.2.1. By Drug
        • 13.8.3.2.2. By Route of Administration
        • 13.8.3.2.3. By Distribution Channel

14. Europe Vaginal Antifungals Market Analysis 2019-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 14.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
    • 14.3.1. By Country
      • 14.3.1.1. Germany
      • 14.3.1.2. Italy
      • 14.3.1.3. France
      • 14.3.1.4. U.K.
      • 14.3.1.5. Spain
      • 14.3.1.6. BENELUX
      • 14.3.1.7. Russia
      • 14.3.1.8. Rest of Europe
    • 14.3.2. By Drug
    • 14.3.3. By Route of Administration
    • 14.3.4. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Drug
    • 14.4.3. By Route of Administration
    • 14.4.4. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Germany Vaginal Antifungals Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast By Market Taxonomy
        • 14.8.1.2.1. By Drug
        • 14.8.1.2.2. By Route of Administration
        • 14.8.1.2.3. By Distribution Channel
    • 14.8.2. Italy Vaginal Antifungals Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast By Market Taxonomy
        • 14.8.2.2.1. By Drug
        • 14.8.2.2.2. By Route of Administration
        • 14.8.2.2.3. By Distribution Channel
    • 14.8.3. France Vaginal Antifungals Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast By Market Taxonomy
        • 14.8.3.2.1. By Drug
        • 14.8.3.2.2. By Route of Administration
        • 14.8.3.2.3. By Distribution Channel
    • 14.8.4. U.K. Vaginal Antifungals Market Analysis
      • 14.8.4.1. Introduction
      • 14.8.4.2. Market Analysis and Forecast By Market Taxonomy
        • 14.8.4.2.1. By Drug
        • 14.8.4.2.2. By Route of Administration
        • 14.8.4.2.3. By Distribution Channel
    • 14.8.5. Spain Vaginal Antifungals Market Analysis
      • 14.8.5.1. Introduction
      • 14.8.5.2. Market Analysis and Forecast By Market Taxonomy
        • 14.8.5.2.1. By Drug
        • 14.8.5.2.2. By Route of Administration
        • 14.8.5.2.3. By Distribution Channel
    • 14.8.6. BENELUX Vaginal Antifungals Market Analysis
      • 14.8.6.1. Introduction
      • 14.8.6.2. Market Analysis and Forecast By Market Taxonomy
        • 14.8.6.2.1. By Drug
        • 14.8.6.2.2. By Route of Administration
        • 14.8.6.2.3. By Distribution Channel
    • 14.8.7. Russia Vaginal Antifungals Market Analysis
      • 14.8.7.1. Introduction
      • 14.8.7.2. Market Analysis and Forecast By Market Taxonomy
        • 14.8.7.2.1. By Drug
        • 14.8.7.2.2. By Route of Administration
        • 14.8.7.2.3. By Distribution Channel

15. East Asia Vaginal Antifungals Market Analysis 2019-2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 15.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
    • 15.3.1. By Country
      • 15.3.1.1. China
      • 15.3.1.2. Japan
      • 15.3.1.3. South Korea
    • 15.3.2. By Drug
    • 15.3.3. By Route of Administration
    • 15.3.4. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Drug
    • 15.4.3. By Route of Administration
    • 15.4.4. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. China Vaginal Antifungals Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast By Market Taxonomy
        • 15.8.1.2.1. By Drug
        • 15.8.1.2.2. By Route of Administration
        • 15.8.1.2.3. By Distribution Channel
    • 15.8.2. Japan Vaginal Antifungals Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast By Market Taxonomy
        • 15.8.2.2.1. By Drug
        • 15.8.2.2.2. By Route of Administration
        • 15.8.2.2.3. By Distribution Channel
    • 15.8.3. South Korea Vaginal Antifungals Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast By Market Taxonomy
        • 15.8.3.2.1. By Drug
        • 15.8.3.2.2. By Route of Administration
        • 15.8.3.2.3. By Distribution Channel

16. South Asia Vaginal Antifungals Market Analysis 2019-2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 16.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Indonesia
      • 16.3.1.3. Malaysia
      • 16.3.1.4. Thailand
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Drug
    • 16.3.3. By Route of Administration
    • 16.3.4. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Drug
    • 16.4.3. By Route of Administration
    • 16.4.4. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. India Vaginal Antifungals Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast By Market Taxonomy
        • 16.8.1.2.1. By Drug
        • 16.8.1.2.2. By Route of Administration
        • 16.8.1.2.3. By Distribution Channel
    • 16.8.2. Indonesia Vaginal Antifungals Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast By Market Taxonomy
        • 16.8.2.2.1. By Drug
        • 16.8.2.2.2. By Route of Administration
        • 16.8.2.2.3. By Distribution Channel
    • 16.8.3. Malaysia Vaginal Antifungals Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast By Market Taxonomy
        • 16.8.3.2.1. By Drug
        • 16.8.3.2.2. By Route of Administration
        • 16.8.3.2.3. By Distribution Channel
    • 16.8.4. Thailand Vaginal Antifungals Market Analysis
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast By Market Taxonomy
        • 16.8.4.2.1. By Drug
        • 16.8.4.2.2. By Route of Administration
        • 16.8.4.2.3. By Distribution Channel

17. Oceania Vaginal Antifungals Market 2019-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 17.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
    • 17.3.1. By Country
      • 17.3.1.1. Australia
      • 17.3.1.2. New Zealand
    • 17.3.2. By Drug
    • 17.3.3. By Route of Administration
    • 17.3.4. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Drug
    • 17.4.3. By Route of Administration
    • 17.4.4. By Distribution Channel
  • 17.5. Key Market Participants - Intensity Mapping
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Country Level Analysis & Forecast
    • 17.7.1. Australia Vaginal Antifungals Market Analysis
      • 17.7.1.1. Introduction
      • 17.7.1.2. Market Analysis and Forecast By Market Taxonomy
        • 17.7.1.2.1. By Drug
        • 17.7.1.2.2. By Route of Administration
        • 17.7.1.2.3. By Distribution Channel
    • 17.7.2. New Zealand Vaginal Antifungals Market Analysis
      • 17.7.2.1. Introduction
      • 17.7.2.2. Market Analysis and Forecast By Market Taxonomy
        • 17.7.2.2.1. By Drug
        • 17.7.2.2.2. By Route of Administration
        • 17.7.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Vaginal Antifungals Market Analysis 2019-2032

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 18.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
    • 18.3.1. By Country
      • 18.3.1.1. GCC Countries
      • 18.3.1.2. Turkiye
      • 18.3.1.3. South Africa
      • 18.3.1.4. North Africa
      • 18.3.1.5. Rest of Middle East and Africa
    • 18.3.2. By Drug
    • 18.3.3. By Route of Administration
    • 18.3.4. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Drug
    • 18.4.3. By Route of Administration
    • 18.4.4. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. GCC Countries Vaginal Antifungals Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast By Market Taxonomy
        • 18.8.1.2.1. By Drug
        • 18.8.1.2.2. By Route of Administration
        • 18.8.1.2.3. By Distribution Channel
    • 18.8.2. Turkiye Vaginal Antifungals Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast By Market Taxonomy
        • 18.8.2.2.1. By Drug
        • 18.8.2.2.2. By Route of Administration
        • 18.8.2.2.3. By Distribution Channel
    • 18.8.3. South Africa Vaginal Antifungals Market Analysis
      • 18.8.3.1. Introduction
      • 18.8.3.2. Market Analysis and Forecast By Market Taxonomy
        • 18.8.3.2.1. By Drug
        • 18.8.3.2.2. By Route of Administration
        • 18.8.3.2.3. By Distribution Channel
    • 18.8.4. North Africa Vaginal Antifungals Market Analysis
      • 18.8.4.1. Introduction
      • 18.8.4.2. Market Analysis and Forecast By Market Taxonomy
        • 18.8.4.2.1. By Drug
        • 18.8.4.2.2. By Route of Administration
        • 18.8.4.2.3. By Distribution Channel

19. Market Structure Analysis

  • 19.1. Market Analysis By Tier of Companies
  • 19.2. Market Concentration
  • 19.3. Market Share Analysis of Top Players
  • 19.4. Market Presence Analysis

20. Competition Analysis

  • 20.1. Competition Dashboard
  • 20.2. Competition Benchmarking
  • 20.3. Competition Deep Dive
    • 20.3.1. Pfizer Inc.
      • 20.3.1.1. Overview
      • 20.3.1.2. Product Portfolio
      • 20.3.1.3. Sales Footprint
      • 20.3.1.4. Key Financials
      • 20.3.1.5. SWOT Analysis
      • 20.3.1.6. Strategic Overview
    • 20.3.2. Bausch Health Companies Inc
      • 20.3.2.1. Overview
      • 20.3.2.2. Product Portfolio
      • 20.3.2.3. Sales Footprint
      • 20.3.2.4. Key Financials
      • 20.3.2.5. SWOT Analysis
      • 20.3.2.6. Strategic Overview
    • 20.3.3. ANI Pharmaceuticals, Inc.
      • 20.3.3.1. Overview
      • 20.3.3.2. Product Portfolio
      • 20.3.3.3. Sales Footprint
      • 20.3.3.4. Key Financials
      • 20.3.3.5. SWOT Analysis
      • 20.3.3.6. Strategic Overview
    • 20.3.4. Hikma Pharmaceuticals Plc
      • 20.3.4.1. Overview
      • 20.3.4.2. Product Portfolio
      • 20.3.4.3. Sales Footprint
      • 20.3.4.4. Key Financials
      • 20.3.4.5. SWOT Analysis
      • 20.3.4.6. Strategic Overview
    • 20.3.5. Lupin Limited
      • 20.3.5.1. Overview
      • 20.3.5.2. Product Portfolio
      • 20.3.5.3. Sales Footprint
      • 20.3.5.4. Key Financials
      • 20.3.5.5. SWOT Analysis
      • 20.3.5.6. Strategic Overview
    • 20.3.6. Mycovia Pharmaceuticals, Inc.
      • 20.3.6.1. Overview
      • 20.3.6.2. Product Portfolio
      • 20.3.6.3. Sales Footprint
      • 20.3.6.4. Key Financials
      • 20.3.6.5. SWOT Analysis
      • 20.3.6.6. Strategic Overview
    • 20.3.7. Glenmark Pharmaceuticals Limited
      • 20.3.7.1. Overview
      • 20.3.7.2. Product Portfolio
      • 20.3.7.3. Sales Footprint
      • 20.3.7.4. Key Financials
      • 20.3.7.5. SWOT Analysis
      • 20.3.7.6. Strategic Overview
    • 20.3.8. Unique Pharmaceuticals
      • 20.3.8.1. Overview
      • 20.3.8.2. Product Portfolio
      • 20.3.8.3. Sales Footprint
      • 20.3.8.4. Key Financials
      • 20.3.8.5. SWOT Analysis
      • 20.3.8.6. Strategic Overview
    • 20.3.9. PEPTONIC medical AB
      • 20.3.9.1. Overview
      • 20.3.9.2. Product Portfolio
      • 20.3.9.3. Sales Footprint
      • 20.3.9.4. Key Financials
      • 20.3.9.5. SWOT Analysis
      • 20.3.9.6. Strategic Overview
    • 20.3.10. Aurobindo Pharma Limited
      • 20.3.10.1. Overview
      • 20.3.10.2. Product Portfolio
      • 20.3.10.3. Sales Footprint
      • 20.3.10.4. Key Financials
      • 20.3.10.5. SWOT Analysis
      • 20.3.10.6. Strategic Overview
    • 20.3.11. Dr. Reddy's Laboratories
      • 20.3.11.1. Overview
      • 20.3.11.2. Product Portfolio
      • 20.3.11.3. Sales Footprint
      • 20.3.11.4. Key Financials
      • 20.3.11.5. SWOT Analysis
      • 20.3.11.6. Strategic Overview
    • 20.3.12. SCYNEXIS, Inc.
      • 20.3.12.1. Overview
      • 20.3.12.2. Product Portfolio
      • 20.3.12.3. Sales Footprint
      • 20.3.12.4. Key Financials
      • 20.3.12.5. SWOT Analysis
      • 20.3.12.6. Strategic Overview
    • 20.3.13. Basilea Pharmaceutica Ltd.
      • 20.3.13.1. Overview
      • 20.3.13.2. Product Portfolio
      • 20.3.13.3. Sales Footprint
      • 20.3.13.4. Key Financials
      • 20.3.13.5. SWOT Analysis
      • 20.3.13.6. Strategic Overview
    • 20.3.14. Astellas Pharma Inc.
      • 20.3.14.1. Overview
      • 20.3.14.2. Product Portfolio
      • 20.3.14.3. Sales Footprint
      • 20.3.14.4. Key Financials
      • 20.3.14.5. SWOT Analysis
      • 20.3.14.6. Strategic Overview
    • 20.3.15. Grupo Ferrer Internacional, S.A.
      • 20.3.15.1. Overview
      • 20.3.15.2. Product Portfolio
      • 20.3.15.3. Sales Footprint
      • 20.3.15.4. Key Financials
      • 20.3.15.5. SWOT Analysis
      • 20.3.15.6. Strategic Overview
    • 20.3.16. Pacgen Life Science Corporation
      • 20.3.16.1. Overview
      • 20.3.16.2. Product Portfolio
      • 20.3.16.3. Sales Footprint
      • 20.3.16.4. Key Financials
      • 20.3.16.5. SWOT Analysis
      • 20.3.16.6. Strategic Overview
    • 20.3.17. NovaDigm Therapeutics, Inc.
      • 20.3.17.1. Overview
      • 20.3.17.2. Product Portfolio
      • 20.3.17.3. Sales Footprint
      • 20.3.17.4. Key Financials
      • 20.3.17.5. SWOT Analysis
      • 20.3.17.6. Strategic Overview
    • 20.3.18. Cidara Therapeutics, Inc.
      • 20.3.18.1. Overview
      • 20.3.18.2. Product Portfolio
      • 20.3.18.3. Sales Footprint
      • 20.3.18.4. Key Financials
      • 20.3.18.5. SWOT Analysis
      • 20.3.18.6. Strategic Overview
    • 20.3.19. Amplyx Pharmaceuticals Inc.
      • 20.3.19.1. Overview
      • 20.3.19.2. Product Portfolio
      • 20.3.19.3. Sales Footprint
      • 20.3.19.4. Key Financials
      • 20.3.19.5. SWOT Analysis
      • 20.3.19.6. Strategic Overview

21. Assumptions and Acronyms Used

22. Research Methodology